* Singular Genomics Systems Inc OMIC.OQ reported a
quarterly
adjusted loss of 32 cents per share for the quarter ended in
December, lower than the same quarter last year, when the
company reported EPS of -29 cents. The mean expectation of
three analysts for the quarter was for a loss of 34 cents per
share. Wall Street expected results to range from -44 cents
to -29 cents per share.
* Revenue rose 41.3% to $1.08 million from a year ago;
analysts
expected $731.33 thousand.
* Singular Genomics Systems Inc's reported EPS for the
quarter was
a loss of 32 cents.
* The company reported a quarterly loss of $23.25 million.
* Singular Genomics Systems Inc shares had risen by 8.7%
this
quarter.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by
about 4% in
the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "hold"
Wall Street's median 12-month price target for Singular Genomics
Systems Inc is $0.63
This summary was machine generated from LSEG data March 18 at
09:01 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Dec. 31 2023 -0.34 -0.32 Beat
Sep. 30 2023 -0.38 -0.31 Beat
Jun. 30 2023 -0.37 -0.35 Beat
Mar. 31 2023 -0.35 -0.33 Beat